The Effects of Age on Prostatic Responses to Oxytocin and the Effects of Antagonists.

BPH LUTS oxytocin oxytocin receptor antagonists

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
01 Nov 2023
Historique:
received: 19 09 2023
revised: 18 10 2023
accepted: 24 10 2023
medline: 25 11 2023
pubmed: 25 11 2023
entrez: 25 11 2023
Statut: epublish

Résumé

Benign prostatic hyperplasia (BPH) is an age-related enlargement of the prostate with urethral obstruction that predominantly affects the middle-aged and older male population, resulting in disruptive lower urinary tract symptoms (LUTS), thus creating a profound impact on an individual's quality of life. The development of LUTS may be linked to overexpression of oxytocin receptors (OXTR), resulting in increased baseline myogenic tone within the prostate. Thus, it is hypothesised that targeting OXTR using oxytocin receptor antagonists (atosiban, cligosiban, and β-Mercapto-β,β-cyclopentamethylenepropionyl1, O-Me-Tyr2, Orn8]-Oxytocin (ßMßßC)), may attenuate myogenic tone within the prostate. Organ bath and immunohistochemistry techniques were conducted on prostate tissue from young and older rats. Our contractility studies demonstrated that atosiban significantly decreased the frequency of spontaneous contractions within the prostate of young rats (****

Identifiants

pubmed: 38001957
pii: biomedicines11112956
doi: 10.3390/biomedicines11112956
pmc: PMC10669827
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Deutsche Forschungsgemeinschaft (GRK 1871) and Monash University, Australia, to the International Research Training Group (IRTG) between Justus-Liebig University Giessen and Monash University
ID : GRK1871

Références

Adv Exp Med Biol. 1997;424:253-64
pubmed: 9361803
Rev Urol. 2007 Fall;9(4):181-90
pubmed: 18231614
Anat Histol Embryol. 2007 Oct;36(5):361-5
pubmed: 17845226
Front Endocrinol (Lausanne). 2020 Oct 22;11:565731
pubmed: 33193084
J Sex Med. 2014 Jun;11(6):1554-66
pubmed: 24708055
J Cell Mol Med. 2007 Jan-Feb;11(1):96-110
pubmed: 17367504
Prostate. 2000 Jan;42(1):45-55
pubmed: 10579798
Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5
pubmed: 17049716
Ann N Y Acad Sci. 2009 Feb;1155:174-86
pubmed: 19250203
J Cell Biol. 1991 Sep;114(6):1113-24
pubmed: 1910049
Urology. 2003 Apr;61(4 Suppl 1):2-7
pubmed: 12657354
Sci Rep. 2021 Mar 18;11(1):6352
pubmed: 33737570
Neurourol Urodyn. 2015 Jun;34(5):482-8
pubmed: 24436088
Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16502-7
pubmed: 25378700
Int J Impot Res. 2008 Dec;20 Suppl 3:S11-8
pubmed: 19002119
J Sex Med. 2019 Aug;16(8):1188-1198
pubmed: 31351660
Clin Exp Pharmacol Physiol. 2005 Oct;32(10):797-804
pubmed: 16173939
Endocr Regul. 2005 Sep;39(3):97-105
pubmed: 16468232
J Gen Intern Med. 1998 Mar;13(3):159-66
pubmed: 9541372
Eur J Pharmacol. 1992 Jun 5;216(2):311-3
pubmed: 1397015
J Sex Med. 2018 Dec;15(12):1698-1706
pubmed: 30527053
J Urol. 2011 May;185(5):1793-803
pubmed: 21420124
Mol Cell Endocrinol. 2017 Jul 5;449:56-63
pubmed: 28119132
Hum Reprod Update. 2006 Jul-Aug;12(4):437-48
pubmed: 16436468
J Endocrinol. 1998 Feb;156(2):223-9
pubmed: 9518866
J Urol. 2012 Jun;187(6):2254-60
pubmed: 22503041
Front Physiol. 2020 May 06;11:382
pubmed: 32435202
J Urol. 2001 Aug;166(2):550-2; discussion 553
pubmed: 11458066
Am J Physiol Renal Physiol. 2014 Oct 1;307(7):F823-32
pubmed: 25056351
Can J Physiol Pharmacol. 2006 Mar-Apr;84(3-4):287-97
pubmed: 16902576
Mol Cells. 2010 Feb 28;29(2):99-104
pubmed: 20127285
Horm Behav. 2006 Nov;50(4):506-17
pubmed: 16890230
Br J Pharmacol. 2008 Sep;155(1):118-26
pubmed: 18552879
Int J Mol Sci. 2022 Jan 21;23(3):
pubmed: 35163140
ANZ J Surg. 2018 Jan;88(1-2):95-99
pubmed: 28317227
Nat Rev Neurosci. 2006 Feb;7(2):126-36
pubmed: 16429122
Biol Reprod. 1997 Feb;56(2):416-22
pubmed: 9116141
J West Afr Coll Surg. 2016 Oct-Dec;6(4):1-30
pubmed: 29181363
J Mol Biol. 2013 Jul 10;425(13):2288-98
pubmed: 23602809
J Biol Chem. 2011 Apr 29;286(17):14737-43
pubmed: 21343284
Front Neuroendocrinol. 2018 Oct;51:14-24
pubmed: 29054552
Front Neurosci. 2015 Sep 24;9:335
pubmed: 26441508
Cell Tissue Res. 2004 Nov;318(2):375-82
pubmed: 15459766
J Urol. 2002 Jul;168(1):315-22
pubmed: 12050563
Front Endocrinol (Lausanne). 2018 Aug 03;9:403
pubmed: 30123183
Mol Hum Reprod. 1998 Jun;4(6):527-32
pubmed: 9665335
Birth Gaz. 1996 Winter;13(1):28-30
pubmed: 9250043
J Recept Signal Transduct Res. 2008;28(1-2):15-28
pubmed: 18437627
Eur Urol. 2012 May;61(5):994-1003
pubmed: 22405510
J Urol. 1984 Sep;132(3):474-9
pubmed: 6206240

Auteurs

Masroor Badshah (M)

Hudson Institute of Medical Research, Monash University, Clayton, VIC 3168, Australia.

Jibriil Ibrahim (J)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, VIC 3052, Australia.

Nguok Su (N)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, VIC 3052, Australia.

Penny Whiley (P)

Hudson Institute of Medical Research, Monash University, Clayton, VIC 3168, Australia.

Michael Whittaker (M)

Drug, Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Parkville, VIC 3052, Australia.

Betty Exintaris (B)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, VIC 3052, Australia.

Classifications MeSH